Nordic Nanovector appoints Dr Christine Wilkinson Blanc as CMO

Nordic Nanovector ASA announces that Dr Christine Wilkinson Blanc has been appointed Chief Medical Officer with immediate effect. Dr Wilkinson Blanc is a seasoned pharmaceutical physician with broad experience in oncology and haematology with both large pharmaceutical and emerging biotechnology companies. She has over 25 years of experience in the pharmaceutical industry and has led multiple clinical studies across all phases for a wide range of indications.

Dr Wilkinson Blanc joins us through her relationship with Weatherden, a specialist clinical development consulting and execution company. She has been Medical Director of Phi-Medics for 10 years, during which time she has provided clinical development consultancy services across oncology and haematology to pharma and biotech companies. The clients she has supported include Roche, Pierre Fabre, Innate Pharma, IPSEN and Antisoma. She was also the Chief Medical Officer of Psioxus Therapeutics between 2013 and 2016.

Prior to this, Dr Wilkinson Blanc was Medical Director in Oncology for a number of companies including Ariad Pharma, Roche, GE Healthcare and Aventis.

Dr Wilkinson Blanc gained her medical qualification, as well as a specialisation in Medical Biology, at the Universities of medicine of Lille and Lyon, France.

Dr Wilkinson Blanc will work with Dr Dominic Smethurst, Nordic Nanovector’s current Interim CMO for a short period to ensure a smooth handover of activities.

Lars Nieba, Interim Chief Executive Officer, commented: “I would like to thank Dominic his dedication and valuable contributions to the advancement of the Company. I am very pleased that Christine has joined Nordic Nanovector as CMO. Her vast experience in clinical development, particularly in oncology and haematology, will be invaluable as we focus our resources and energy on completing the PARADIGME study.”

Dr Christine Wilkinson Blanc said: “I am excited to be joining Nordic Nanovector as it works to ensure the completion of PARADIGME in a timely fashion. Betalutin is an exciting one-time treatment which has shown very promising efficacy data in advanced follicular lymphoma. With a clear development path following the recent successful Interim Analysis, I am looking forward to making an important contribution to bring this novel drug candidate to this fragile patient population, which is clearly in need of much improved treatment options.”

-Biospace